Skip to main content
Signal8

CytoDyn Inc. (CYDY) Form 8-K — Nov 17, 2026

$CYDYForm 8-KItems 5.02, 7.01, 9.01Filed Nov 17, 2026, 4:33 PM ET0001175680-26-000042Original filing

CytoDyn announced on November 17, 2026 the appointment of Lauren Wilcoxen, Ph.D. as Chief Operating Officer and Head of Regulatory Affairs, effective November 20, 2026. Dr. Wilcoxen most recently served as SVP of Regulatory Affairs at Xilio Therapeutics and previously helped secure FDA approval of a checkpoint inhibitor at Checkpoint Therapeutics before its acquisition by Sun Pharmaceutical.

Key figures

Base Salary
425000
Fiscal Year End
May 31, 2027
Option Vesting
4-year vesting
Target Annual Bonus
40% of base salary
Stock Options Granted
4500000

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.